Thymosin beta-4: what the research shows

  • By Reed Calder
  • Last reviewed Nov 12, 2026
  • 38 studies and official documents checked

In short

Thymosin beta-4 is a natural protein of 43 amino acids, first isolated from the thymus and later found in most cells. Lab-made versions have been tested in people as eye drops, a skin gel and IV infusions, mostly in trials run by the companies developing them. The results are mixed. Two large dry-eye trials (601 and 700 people) posted group averages no better than placebo, an 18-person trial in a corneal disease just missed its main test (6 of 10 healed against 1 of 8, p = 0.0656), and in a 96-person heart-attack trial the damaged area was smaller only in the 43 people dosed within 8 hours. Mice bred without it develop normally. We found no human study of injection under the skin or of tendon or muscle injuries. It isn’t FDA-approved, and TB-500 is a different, 7-amino-acid fragment.

EvidenceCellAnimalHumaneye drops, gel and IV trials; none of injection under the skin

You’ll often read that thymosin beta-4 heals tendons, muscle and the heart, regrows hair, builds blood vessels, is “vital” for repair and is the same as TB-500. This page covers what it is, what each human trial found, where the heart, eye and cancer results point different ways, and where it stands legally.

Names and forms you’ll see

The names on thymosin beta-4 products
Name What it is Studied in people?
Thymosin beta-4, Tβ4, TB4 The natural 43-amino-acid protein, made from an X-linked gene (TMSB4X) (Banerjee et al., 2012; Chi et al., 2017) Yes: eye drops, skin gel, IV
Timbetasin The drug name the FDA’s substance registry gives the same protein Same
RGN-259 The 0.1% eye-drop form, developed by ReGenTree (trial record) Yes
NL005, recombinant human thymosin beta-4 The injectable form from Beijing Northland Biotech, given by IV. Its first-in-human paper describes it as 44 amino acids, one more than the natural protein, with activity the authors call identical (Wang et al., 2021; Zhang et al., 2025) Yes
TB-500, Ac-LKKTETQ A different molecule: a 7-amino-acid fragment (Ho et al., 2012) Three patients, in a mix; one registry record we couldn’t verify
Thymosin alpha-1 A different thymus peptide with its own entry on this site Not this page
Vials and sprays sold as TB4 or TB500 Forms sold online; one 2018 analysis of three such preparations found the full-length protein (Janvier et al., 2018) No study of these products found

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The registry also holds a separate record named THYMOSIN .BETA.-4. A vial showing 77591-33-4 is labeled as the full protein, not TB-500.

Thymosin beta-4 CAS numbers
Form CAS number Registry record
Thymosin beta-4, the full 43-amino-acid protein (drug name timbetasin) 77591-33-4 FDA GSRS
TB-500 (Ac-LKKTETQ, 7 amino acids) 885340-08-9 FDA GSRS

What thymosin beta-4 is

Thymosin beta-4 is a protein of 43 amino acids. By its PubChem record it is C212H350N56O78S and weighs about 4,963 daltons. It was first isolated from the thymus gland and later found in most cells, where it mainly binds actin, the protein that gives cells their shape and lets them move (Mora et al., 1997).

Platelets, macrophages and other cells release it after an injury. The repair story rests on that: it binds actin, helps cells migrate and has been reported to cut scar-forming cells and inflammation (Goldstein et al., 2012). That review shares authors, Sosne and Kleinman, with the trial reports below.

The “vital for repair” idea has a hard check. Mice with the gene deleted everywhere, or only in the heart, were born at normal ratios and had normal hearts, vessels and adult heart function. The authors concluded it is dispensable for heart and vessel development (Banerjee et al., 2012).

What has been studied

In people: trials of the protein, 2006 to 2026

Human trials of full thymosin beta-4
Trial People Form What it found
Ruff et al., 2010 40 healthy volunteers (four groups of 10) IV infusion, once and then daily for 14 days Mild or moderate events, none serious; half-life rose with dose
Wang et al., 2021 84 healthy volunteers (54 single dose, 30 repeated) Recombinant IV (NL005), up to 10 days Mild to moderate events, none serious; no obvious build-up
Guarnera et al., 2010 73 people with venous leg ulcers (72 on the registry) Skin gel, up to 84 days Safety like placebo; 0.03% “may have the potential” to speed healing. The registry shows closure at day 84 in 12 of 55 people on the gel (all strengths pooled) and 4 of 17 on placebo (NCT00832091)
Pressure ulcers, 2006 to 2008 72 people Skin gel at three strengths, up to 84 days Registry primary outcome is safety; the healing result is in the developers’ review: almost a month faster in those who healed (Treadwell et al., 2012)
Epidermolysis bullosa, 2006 to 2012 30 people Skin gel, up to 56 days Stopped for “lack of patient availability and expiration of study drug”; primary outcome was safety; we found no efficacy paper
Sosne et al., 2015 9 people with severe dry eye (12 treated eyes, 6 vehicle) Eye drops, 28 days 35.1% less discomfort and 59.1% less staining than vehicle at day 56 (P = 0.0141, 0.0108); a very small trial
Sosne and Ousler, 2015 72 people with dry eye Eye drops, 28 days Missed both primary goals; some secondary measures improved, such as 27% less discomfort in the day-28 challenge (P = 0.0244)
ARISE-1, 2015 to 2016 317 people with dry eye Eye drops Completed; no results posted and no journal paper found
ARISE-2, 2016 to 2018 601 people with dry eye Eye drops Group averages for both main measures within about 0.1 point of placebo; no journal paper found
ARISE-3, 2019 to 2021 700 people with dry eye Eye drops Group averages for both main measures within 0.05 point of placebo; no journal paper found
Sosne et al., 2022 18 people with neurotrophic keratopathy Eye drops, 4 weeks Healed in 6 of 10 against 1 of 8 on placebo; main test p = 0.0656, short of 0.05; the registry says the trial ended for a “business decision” (SEER-1)
SEER-2, 2023 to 2026 70 people with neurotrophic keratopathy Eye drops, 28 days Completed July 28, 2026; no results posted as of November 12, 2026
Diabetic corneal wounds, 2007 to 2009 12 people Eye drops Stopped for slow recruitment; primary outcome was safety
Zhang et al., 2025 96 people after a heart attack (STEMI) Recombinant IV, first dose within 8 hours of the artery-opening procedure in the key group Damaged area smaller at 90 days in the 43 dosed within 8 hours; not significantly different across all 96
Heart attack, Phase 2a, Phase 2b 62 and 90 people Recombinant IV for 7 days Both completed; no results posted. A third trial of 189 people has not started recruiting (record)
  • Who ran them. The registry lists RegeneRx, ReGenTree and Beijing Northland Biotech as sponsors. Employees of ReGenTree and HLB Therapeutics are authors of the keratopathy paper, and employees of Beijing Northland are authors of the heart-attack and healthy-volunteer papers (Sosne et al., 2022; Zhang et al., 2025; Wang et al., 2021). We found no independent trial.
  • Only on a registry. The three ARISE dry-eye trials and the pressure-ulcer trial have registry entries but no journal paper of their own that we found.
  • What none tested. Tendon, ligament or muscle injuries, hair, injection under the skin or into muscle, and long-term use.

EvidenceCellAnimalHumanfull protein only; drops, gel and IV; company-run trials

In mice, rats and pigs

  • Skin wounds. The developers’ review reports faster healing of skin wounds in normal, steroid-treated, diabetic and aged rodents (Treadwell et al., 2012).
  • Heart, mice. A 7-day course prevented heart dysfunction and fibrosis 28 days after a blocked-and-reopened artery, and a permanent-blockage model improved at 8 weeks (Zhang et al., 2025).
  • Heart, pigs. In pigs on heart-lung bypass, it didn’t reduce cell death, and heart function and blood flow were similar to vehicle. At high doses, lab tests showed it narrowed mesenteric arteries, widened coronary arteries and reduced clot firmness when an antiplatelet drug was present (Stark et al., 2016).
  • Muscle. In dystrophic mice given 150 micrograms twice a week for 6 months, regenerating muscle fibers increased, but strength, heart function and fibrosis did not improve (Spurney et al., 2010).
  • Hair. Mice engineered to overproduce it regrew hair faster and mice without it regrew it slower; earlier rodent work reported hair growth (Gao et al., 2015; Philp et al., 2004).
  • Where it goes. After 400 micrograms into the abdomen of mice, blood levels rose within 2 minutes and lasted about 40 minutes; 83% of the dose was recovered, 44.6% in urine, 1.4% in blood and 37.5% in organs including brain, heart and kidney (Mora et al., 1997).

EvidenceCellAnimalHumanmice, rats and pigs

In tumors and cells

  • Higher in some cancers. The gene was more active in head and neck tumors, and higher levels went with shorter overall and recurrence-free survival (Chi et al., 2017). It was higher in lung cancer tissue, and silencing it slowed cell growth and tumors (Huang et al., 2016).
  • Spread in mice. In a mouse model of diffuse gastric cancer, the gene promoted spread to the liver (An et al., 2021).
  • The opposite result. Given as a protein to mice with lung fibrosis and lung cancer, it slowed tumor growth and eased the fibrosis (Yu et al., 2023).

EvidenceCellAnimalHumantumor samples, cell lines and mouse models; none tested injected protein in people

Most human trials were run by the companies developing the protein, and several results appear only on a registry. A result for eye drops or a gel isn’t a result for an injection (ClinicalTrials.gov search).

The usual claims, checked

Common thymosin beta-4 claims vs the studies
Claim Verdict What the studies found
It is a natural protein, made in most cells Supported Yes. It is a 43-amino-acid protein first isolated from the thymus and later found in most cells, where it binds actin (Mora et al., 1997). Its gene is on the X chromosome (Banerjee et al., 2012). Whether adding more does anything is what the rest of this table asks
It heals chronic wounds and ulcers Mixed In rodents it sped skin-wound healing, per the developers’ review (Treadwell et al., 2012). In a 73-person venous-ulcer trial, 0.03% “may have the potential” to speed healing (Guarnera et al., 2010), but the registry shows closure at day 84 in 12 of 55 on the gel (strengths pooled) and 4 of 17 on placebo (NCT00832091). The ulcer trials list safety as their primary outcome on the registry, and we found no independent trial
It treats dry eye Contradicted The 72-person Phase 2 trial missed both primary goals (Sosne and Ousler, 2015). A 9-person trial reported 35.1% less discomfort and 59.1% less staining at day 56 (Sosne et al., 2015). Then two Phase 3 trials, 601 and 700 people, posted group averages within about 0.1 point of placebo on their registry pages (ARISE-2; ARISE-3); we found no journal paper for either
It heals neurotrophic keratopathy Mixed In 18 people, 6 of 10 healed in 4 weeks against 1 of 8 on placebo; the main test came out at p = 0.0656, short of the usual 0.05 cutoff, and employees of the developer are authors (Sosne et al., 2022). A 70-person follow-up finished on July 28, 2026 with no results posted (SEER-2)
It repairs the heart after a heart attack Mixed In mice it prevented heart dysfunction and fibrosis (Zhang et al., 2025). In pigs on bypass it didn’t reduce cell death or change heart function (Stark et al., 2016). In the 96-person trial the damaged area was smaller only in the 43 people dosed within 8 hours, and not significantly different across all 96 (Zhang et al., 2025)
It is vital for the heart and blood vessels to form Contradicted No. Mice with the gene deleted everywhere, or only in the heart, were born at normal ratios with normal hearts, vessels and adult heart function (Banerjee et al., 2012)
It speeds tendon, ligament and muscle recovery Untested We found no study of the full protein in a person with a tendon, ligament or muscle injury. In dystrophic mice it increased regenerating muscle fibers but didn’t improve strength, heart function or fibrosis (Spurney et al., 2010). A 2026 review found the direct musculoskeletal evidence is limited to cells and rodents (Tham et al., 2026). The tendon study people cite used TB-500, the fragment (Biçer et al., 2026)
It regrows hair Untested Mice engineered to overproduce it regrew hair faster and mice without it regrew it slower (Gao et al., 2015); earlier rodent work reported hair growth (Philp et al., 2004). We found no study of hair in a person
It slows aging Untested We found no study of lifespan or aging after giving thymosin beta-4
It causes cancer Untested No study tested whether injected protein changes cancer risk in people. Its gene is more active in some tumors and tied to worse survival in head and neck cancer (Chi et al., 2017); the gene promoted spread in a mouse gastric-cancer model (An et al., 2021). Yet giving the protein to mice slowed a lung-cancer model (Yu et al., 2023)
It is safe, with no side effects Mixed Short IV trials in 40 and 84 healthy people reported mild to moderate events and none serious (Ruff et al., 2010; Wang et al., 2021). The eye and ulcer trials reported no significant adverse effects (Sosne et al., 2022; Guarnera et al., 2010). The longest course was 84 days of gel, none tested long-term use, and the cancer question is open
It is the same as TB-500 Contradicted No. Thymosin beta-4 has 43 amino acids and TB-500 is a 7-amino-acid fragment, and the FDA’s registry lists them as separate substances (Ho et al., 2012; Tham et al., 2026). The FDA’s risk page names the fragment only (FDA, 2026)
Vials sold as TB-500 or TB4 contain what the label says Mixed One 2018 analysis of internet-bought peptides found the full-length protein in all 3 thymosin beta-4-related preparations, including two labeled TB500, and detected related impurities by mass spectrometry (Janvier et al., 2018). Three preparations from three vendors in Belgium; not a market survey
The online injection protocols come from the research Untested The human trials used IV infusion, skin gel and eye drops. We found no human study of injection under the skin or into muscle
It works better stacked with BPC-157 Untested No study tested the full protein with BPC-157. The one controlled test of the pair is a 2026 rat Achilles-tendon study of BPC-157 and TB-500, the fragment (Biçer et al., 2026). In people, one report gave three patients a mix that included both, with no comparison group (Froum et al., 2026)
It is FDA-approved Contradicted No. The FDA’s approved-drug data return no product under thymosin or thymalfasin (openFDA Drugs@FDA), and its safety-risk page names the TB-500 fragment, not the full protein (FDA, 2026)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

Thymosin beta-4 and TB-500

Thymosin beta-4 compared with TB-500
Thymosin beta-4 TB-500
Size 43 amino acids 7 amino acids, Ac-LKKTETQ (Ho et al., 2012)
FDA substance registry Timbetasin, and a second record named THYMOSIN .BETA.-4 TB-500, a separate record
Trials in people Healthy volunteers, ulcers, eye disease and heart attack (table above) A case report of three patients who got TB-500 in a mix (Froum et al., 2026). One registry record, from a sponsor we couldn’t verify, isn’t counted (NCT07487363)
FDA risk page Not named Named; the FDA said it found no human exposure data (FDA, 2026)
October 2026 HHS policy Not named Named (Reuters, 2026)
Sport Prohibited, and so are its derivatives (WADA, 2026) Prohibited as a derivative

A result for the protein isn’t a result for the fragment. A 2026 review says the two are often conflated and that no validated equivalence exists (Tham et al., 2026). Our TB-500 page covers the fragment, and its tendon study in rats.

What the studies used

Amounts used in the thymosin beta-4 studies
Study What was tested Amount reported
Ruff et al., 2010 Healthy people, IV Four rising dose levels from 42 to 1,260 (the abstract prints the unit as “mg”), once and then daily for 14 days
Wang et al., 2021 Healthy people, recombinant IV Single doses of 0.05 to 25 micrograms per kilogram; 0.5, 2.0 or 5.0 micrograms per kilogram daily for 10 days
Heart attack, Phase 2a Recombinant IV 0.25, 0.5 or 2.0 micrograms per kilogram, continuous for 7 days (registry)
Heart attack, Phase 2b Recombinant IV 0.5 or 1.0 micrograms per kilogram, from 12 hours after the procedure and daily on days 2 to 7 (registry)
Pressure ulcers; Guarnera et al., 2010 Skin gel 0.01%, 0.02% or 0.1% gel once a day for up to 84 days; the venous-ulcer paper highlights 0.03%
Sosne and Ousler, 2015; Sosne et al., 2015; SEER-2 Eye drops 0.1%; 28 days; five or six times a day
Spurney et al., 2010 Dystrophic mice 150 micrograms twice a week for 6 months
Mora et al., 1997 Mice 400 micrograms once, into the abdomen

A dose per kilogram of a mouse, or a percentage in a gel, doesn’t convert into an injection for a person, and no study did that conversion. We found no study of injection under the skin or into muscle. These are amounts from studies, not advice for anyone to use.

Side effects and safety

  • In healthy volunteers. IV courses of up to 14 days caused mild or moderate events and nothing serious (Ruff et al., 2010; Wang et al., 2021). The second study also measured antibodies against the drug; its abstract doesn’t give the result.
  • In patients. The venous-ulcer gel was judged acceptable and comparable to placebo, and the keratopathy authors reported no significant adverse effects (Guarnera et al., 2010; Sosne et al., 2022). The longest course was 84 days.
  • Blood and vessels. In pig work, high doses had vessel and clotting effects in lab tests (Stark et al., 2016).
  • Cancer. The gene is more active in some tumors and promoted spread in one mouse model, while the protein slowed tumors in another (Chi et al., 2017; An et al., 2021; Yu et al., 2023). No study tested injected protein and cancer risk in people.
  • What is in the bottle. The one analysis we found of internet-bought preparations found the full-length protein in all three thymosin beta-4-related products, two of them labeled TB500, plus related impurities (Janvier et al., 2018). Its abstract-wide purity and metal figures weren’t assigned to those products.
  • Not studied. Injection under the skin or into muscle, use beyond 84 days, pregnancy, children, and mixing with other peptides.

Side effects people report from online products aren’t covered here; they come from users, not studies.

Legal and approval status

  • Not an approved drug. The FDA’s approved-drug data return no product under thymosin or thymalfasin (openFDA Drugs@FDA). Its page of bulk substances that may present significant safety risks names the TB-500 fragment, not the full protein (FDA, 2026).
  • Late-stage trials aren’t approval. The eye-drop form has been through Phase 3 trials, and the registry shows SEER-2 completed in July 2026 with no results posted (SEER-2).
  • Not in the October 2026 HHS policy. That temporary policy names TB-500 among six peptides, not the full protein (Reuters, 2026).
  • Sport. The World Anti-Doping Agency’s 2026 list prohibits thymosin-β4 and its derivatives, including TB-500 (WADA, 2026).
  • “Research use only” vials and any use in people outside a trial aren’t approved.

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and registries:

  • Which molecule. Thymosin beta-4 has 43 amino acids and TB-500 has 7. Trial results belong to the full protein as eye drops, a gel or an IV drug.
  • Whose trial. Company staff are authors or sponsors of most trials, and several results exist only on a registry.
  • The route. Drops and gels don’t show what an injection does, and no human study of injection under the skin was found.
  • “Phase 3.” The keratopathy trial called Phase 3 enrolled 18 people and ended early; the large dry-eye Phase 3 trials showed no benefit on group averages.
  • “Vital for repair.” Mice bred without it develop normally.
  • What the vial holds. An analysis found the full-length protein in vials labeled TB500.

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.

Trials under way

One trial of NL005, a recombinant thymosin beta-4, is registered and not yet recruiting: see the list, with sponsor, phase, size and registry links.

Already under way: 1 finished with no results posted.

What’s still unknown

  • Whether the 70-person SEER-2 trial confirms the 18-person keratopathy result.
  • Whether the early-dosing heart-attack result holds in a trial built to test timing.
  • Why the large dry-eye trials didn’t repeat the secondary results of the small ones.
  • Whether any form reaches or helps tendon, ligament or muscle in people; no human study exists.
  • Whether injection under the skin does anything, is absorbed in the same way or is safe.
  • Whether long-term exposure changes cancer risk.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Thymosin beta-4. We recheck every month. Last checked Nov 13, 2026.

Flagged studies that mention Thymosin beta-4

Retracted, withdrawn and flagged studies
Study What it was about Status
Li et al., 2023 Deficiency of endothelial sirtuin1 in mice stimulates skeletal muscle insulin sensitivity by modifying the secretome. Retracted (2026) · notice
Zhang et al., 2021 Tβ4 ameliorates oxidative damage and apoptosis through ERK/MAPK and 5-HT1A signaling pathway in Aβ insulted SH-SY5Y cells. Withdrawn (2021) · notice
Bokor et al., 2018 Molecular Motions and Interactions in Aqueous Solutions of Thymosin-β4 , Stabilin C-Terminal Domain (CTD) and Their 1:1 Complex Studied by 1 H NMR Spectroscopy. Retracted (2020) · notice
Li et al., 2017 MiR-200a mediates protection of thymosin beta 4 in cardiac microvascular endothelial cells as a novel mechanism under hypoxia-reoxygenation injury. Retracted (2019) · notice
Lee et al., 2013 The role of thymosin beta 4 on odontogenic differentiation in human dental pulp cells. Retracted (2025) · notice
Smart et al., 2002 A differential screen for putative targets of the bHLH transcription factor Hand1 in cardiac morphogenesis. Retracted (2002) · notice

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Mora et al., 1997 Int J Immunopharmacol No retraction or concern
Philp et al., 2004 Mech Ageing Dev No retraction or concern
Spurney et al., 2010 PLoS One No retraction or concern
Guarnera et al., 2010 Ann N Y Acad Sci No retraction or concern
Ruff et al., 2010 Ann N Y Acad Sci No retraction or concern
Goldstein et al., 2012 Expert Opin Biol Ther No retraction or concern
Banerjee et al., 2012 Circ Res No retraction or concern
Treadwell et al., 2012 Ann N Y Acad Sci No retraction or concern
Ho et al., 2012 J Chromatogr A No retraction or concern
Sosne et al., 2015 Cornea No retraction or concern
Sosne and Ousler, 2015 Clin Ophthalmol No retraction or concern
Gao et al., 2015 PLoS One No retraction or concern
Stark et al., 2016 Front Pharmacol No retraction or concern
Huang et al., 2016 Acta Biochim Biophys Sin (Shanghai) No retraction or concern
Chi et al., 2017 Sci Rep No retraction or concern
Janvier et al., 2018 Talanta No retraction or concern
An et al., 2021 Mol Carcinog No retraction or concern
Wang et al., 2021 J Cell Mol Med No retraction or concern
Sosne et al., 2022 Int J Mol Sci No retraction or concern
Yu et al., 2023 Int J Mol Sci No retraction or concern
Zhang et al., 2025 Cardiovasc Res No retraction or concern
Biçer et al., 2026 Jt Dis Relat Surg No retraction or concern
Froum et al., 2026 Front Oral Health No retraction or concern
Tham et al., 2026 J Am Acad Orthop Surg No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is thymosin beta-4?

A natural protein of 43 amino acids, first isolated from the thymus and found in most cells, where it mainly binds actin. Lab-made versions have been tested in people as eye drops, a skin gel and IV infusions (Mora et al., 1997; Ruff et al., 2010).

What does thymosin beta-4 do to the body?

Inside cells it binds actin. After an injury it is released by platelets and other cells, and reviews credit it with helping cell movement and cutting scarring and inflammation, though mice bred without it develop normally (Goldstein et al., 2012; Banerjee et al., 2012).

What is thymosin beta-4 used for?

It isn’t approved for any use. It has been tested for skin ulcers, dry eye, a corneal disease and heart attack, and sold online for recovery and hair (Guarnera et al., 2010; Sosne et al., 2022; Zhang et al., 2025).

Does thymosin beta-4 work?

Mixed. A corneal-disease trial of 18 people just missed its main test, two large dry-eye trials posted group averages no better than placebo, and a heart-attack trial was positive only in people dosed within 8 hours (Sosne et al., 2022; ARISE-3; Zhang et al., 2025).

Why is thymosin beta-4 banned?

The World Anti-Doping Agency’s list prohibits thymosin-β4 and its derivatives, including TB-500, as growth factors that could aid tissue recovery (WADA, 2026).

Is thymosin beta-4 the same thing as TB-500?

No. Thymosin beta-4 has 43 amino acids; TB-500 is a 7-amino-acid fragment, and the FDA’s registry lists them separately (Ho et al., 2012; Tham et al., 2026).

Does thymosin beta-4 cause cancer?

Unknown. The gene is more active in some tumors and promoted spread in a mouse model, while the protein slowed tumors in another, and no study tested injected protein in people (Chi et al., 2017; An et al., 2021; Yu et al., 2023).

Is thymosin beta-4 safe?

Not shown beyond short courses. IV courses of up to 14 days in healthy people caused mild or moderate events and nothing serious, and the longest treatment course we found was 84 days of gel (Ruff et al., 2010; Wang et al., 2021).

What are the side effects of thymosin beta-4?

In trials they were mild to moderate and none was serious. Side effects people report from online products come from users, not studies (Ruff et al., 2010; Wang et al., 2021).

What is the thymosin beta-4 dosage?

We don’t give dosing advice. The human trials used IV doses in micrograms per kilogram, skin gels of 0.01 to 0.1% and 0.1% eye drops, and none studied injection under the skin (Wang et al., 2021; Guarnera et al., 2010; Sosne and Ousler, 2015).

Is thymosin beta-4 FDA approved or legal?

It isn’t an approved drug, and the FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA). Our guide to what to look for covers the routes people use.

Does thymosin beta-4 help dry eyes?

Not in the large trials. Two Phase 3 trials of 601 and 700 people posted group averages within about 0.1 point of placebo, after smaller trials reported benefits on some measures (ARISE-2; ARISE-3; Sosne and Ousler, 2015).

Does thymosin beta-4 help the heart after a heart attack?

In mice yes, in pigs no, and in a 96-person trial the damaged area was smaller only in the 43 people dosed within 8 hours (Zhang et al., 2025; Stark et al., 2016).

Does thymosin beta-4 heal tendons or muscle?

We found no study of the full protein in a person with such an injury. In dystrophic mice it didn’t improve strength (Spurney et al., 2010; Tham et al., 2026).

Does thymosin beta-4 grow hair?

In mice engineered to overproduce it, hair regrew faster. We found no study of hair in a person (Gao et al., 2015).

Can thymosin beta-4 be stacked with BPC-157?

No study tested the full protein with BPC-157. The one controlled test used TB-500, the fragment, in rat tendons (Biçer et al., 2026). A 2026 report gave three patients a mix of drugs that included both, with no comparison group (Froum et al., 2026).

How long does thymosin beta-4 stay in the body?

In mice, blood levels lasted about 40 minutes after an injection into the abdomen. In healthy people the half-life rose with the IV dose (Mora et al., 1997; Ruff et al., 2010).

Is thymosin beta-4 the same as thymosin alpha-1?

No. They are different peptides, and the FDA’s risk page lists thymosin alpha-1 separately (FDA, 2026). See the thymosin alpha-1 entry.

Sources

  1. Guarnera G, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-12. PubMed 20536470
  2. Treadwell T, et al. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270:37-44. PubMed 23050815
  3. Sosne G, et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84. PubMed 26056426
  4. Sosne G, et al. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6. PubMed 25826322
  5. Sosne G, et al. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022;24(1):554. PubMed 36613994
  6. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-9. PubMed 20536472
  7. Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. PubMed 34346165
  8. Zhang Y, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758. PubMed 41229390
  9. Banerjee I, et al. Thymosin beta 4 is dispensable for murine cardiac development and function. Circ Res. 2012;110(3):456-64. PubMed 22158707
  10. Stark CK, et al. Systemic Dosing of Thymosin Beta 4 before and after Ischemia Does Not Attenuate Global Myocardial Ischemia-Reperfusion Injury in Pigs. Front Pharmacol. 2016;7:115. PubMed 27199757
  11. Spurney CF, et al. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One. 2010;5(1):e8976. PubMed 20126456
  12. Gao X, et al. Thymosin Beta-4 Induces Mouse Hair Growth. PLoS One. 2015;10(6):e0130040. PubMed 26083021
  13. Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-5. PubMed 15037013
  14. Mora CA, et al. Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice. Int J Immunopharmacol. 1997;19(1):1-8. PubMed 9226473
  15. Yu R, et al. Exogenous Thymosin Beta 4 Suppresses IPF-Lung Cancer in Mice: Possibly Associated with Its Inhibitory Effect on the JAK2/STAT3 Signaling Pathway. Int J Mol Sci. 2023;24(4):3818. PubMed 36835236
  16. Huang D, et al. Thymosin beta 4 silencing suppresses proliferation and invasion of non-small cell lung cancer cells by repressing Notch1 activation. Acta Biochim Biophys Sin (Shanghai). 2016;48(9):788-94. PubMed 27521796
  17. Chi LH, et al. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma. Sci Rep. 2017;7(1):9031. PubMed 28831179
  18. An HW, et al. In vivo CRISPR-Cas9 knockout screening using quantitative PCR identifies thymosin beta-4 X-linked that promotes diffuse-type gastric cancer metastasis. Mol Carcinog. 2021;60(9):597-606. PubMed 34081824
  19. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed 22074294
  20. Tham A, et al. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg. 2026. PubMed 42937313
  21. Janvier S, et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807. PubMed 30029448
  22. Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed 23084823
  23. Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PubMed 42542926
  24. ClinicalTrials.gov. Search for thymosin beta 4 and RGN-259, November 12, 2026: 19 records. Search
  25. ClinicalTrials.gov. Records for ARISE-1 (NCT02597803), November 12, 2026: completed, no results posted. Record
  26. ClinicalTrials.gov. Records for ARISE-2 (NCT02974907) and ARISE-3 (NCT03937882), results posted by the sponsor, ReGenTree, LLC; checked November 12, 2026. ARISE-2 ARISE-3
  27. ClinicalTrials.gov. SEER-1 (NCT02600429), terminated, 18 people; SEER-2 (NCT05555589), completed July 28, 2026, no results posted; checked November 12, 2026. SEER-1 SEER-2
  28. ClinicalTrials.gov. Thymosin beta-4 gel trials: pressure ulcers (NCT00382174), venous stasis ulcers (NCT00832091) and epidermolysis bullosa (NCT00311766); checked November 12, 2026. Pressure ulcers Venous ulcers Epidermolysis bullosa
  29. ClinicalTrials.gov. Thymosin beta-4 eye drops in diabetic corneal wounds (NCT00598871), terminated; checked November 12, 2026. Record
  30. ClinicalTrials.gov. Beijing Northland Biotech heart attack trials: Phase 2a (NCT05485818), Phase 2b (NCT05984134) and a Phase 2 trial not yet recruiting (NCT07586865); checked November 12, 2026. Phase 2a Phase 2b Phase 2, 189 people
  31. ClinicalTrials.gov. TB-500 in adults with stable atherosclerotic cardiovascular disease (NCT07487363), sponsor Hudson Biotech, listed as recruiting; not counted because we couldn’t verify the sponsor, checked November 13, 2026. Record Sponsor search
  32. Froum S, et al. Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health. 2026;7:1907109. PubMed 42876687
  33. U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for thymosin, thymosin beta and thymalfasin, November 12, 2026: no match. openFDA
  34. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  35. World Anti-Doping Agency. 2026 Prohibited List, section S2.3. WADA document
  36. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  37. National Library of Medicine. PubChem compound record: Thymosin Beta 4 (CID 45382195). PubChem
  38. U.S. Food and Drug Administration. Global Substance Registration System: Timbetasin (UNII 2D5MRE3SSY). GSRS
  39. U.S. Food and Drug Administration. Global Substance Registration System: TB-500 (UNII QHK6Z47GTG). GSRS

Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.